Integrated BioPharma Inc (INBP) stock
INBPOTCPharmaceutical PreparationsFiscal year ends June 30
$0.18+0.00 (0.00%)
Close on Oct 19, 2026Market cap $5.59MP/E –Yield –
Integrated BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Integrated BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$2.71M, down 233.9% year over year. For fiscal 2026 it was -$2.71M, down 233.9% from the year before. The highest annual figure on record is $5.78M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$2.71M | -233.9% |
| FY2025 | Jun 30, 2025 | $2.02M | +704.8% |
| FY2024 | Jun 30, 2024 | $251.00K | +109.2% |
| FY2023 | Jun 30, 2023 | $120.00K | -95.6% |
| FY2022 | Jun 30, 2022 | $2.75M | -52.5% |
| FY2021 | Jun 30, 2021 | $5.78M | +77.5% |
| FY2020 | Jun 30, 2020 | $3.26M | +20.5% |
| FY2019 | Jun 30, 2019 | $2.70M | +59.6% |
| FY2018 | Jun 30, 2018 | $1.69M | -46.8% |
| FY2017 | Jun 30, 2017 | $3.19M | +50.8% |
| FY2016 | Jun 30, 2016 | $2.11M | +126.6% |
| FY2015 | Jun 30, 2015 | $933.00K | -31.0% |
| FY2014 | Jun 30, 2014 | $1.35M | +21.1% |
| FY2013 | Jun 30, 2013 | $1.12M | – |
| FY2012 | Jun 30, 2012 | -$506.00K | – |
| FY2011 | Jun 30, 2011 | -$362.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$869.00K | -247.5% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$1.09M | -246.8% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$914.00K | -552.5% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $163.00K | -66.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $589.00K | +46.5% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $739.00K | +108.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $202.00K | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $490.00K | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $402.00K | +408.9% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $355.00K | +706.8% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$452.00K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$54.00K | -280.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $79.00K | -82.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $44.00K | -95.6% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$33.00K | -104.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $30.00K | -94.9% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $438.00K | -66.6% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $992.00K | -42.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $730.00K | -41.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $585.00K | -61.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.31M | +112.3% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $1.72M | +79.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $1.24M | +3.2% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.51M | +217.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $618.00K | +7.7% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $960.00K | -22.4% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $1.21M | +147.4% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $476.00K | +17.5% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $574.00K | -8.2% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.24M | +87.4% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $487.00K | +146.0% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $405.00K | +91.9% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $625.00K | -24.7% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $660.00K | +53.8% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $198.00K | -65.3% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $211.00K | -84.5% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $830.00K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $429.00K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $570.00K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $1.36M | – |
See a number that looks wrong?